Ryan Fukushima Sells 41,095 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) CEO Ryan Fukushima sold 41,095 shares of the firm’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total transaction of $2,038,722.95. Following the completion of the sale, the chief executive officer owned 562,463 shares in the company, valued at $27,903,789.43. This represents a 6.81% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Ryan Fukushima also recently made the following trade(s):

• On Friday, August 7th, Ryan Fukushima sold 20,000 shares of Tempus AI stock. The stock was sold at an average price of $50.04, for a total transaction of $1,000,800.00.
• On Monday, August 3rd, Ryan Fukushima sold 23,818 shares of Tempus AI stock. The stock was sold at an average price of $46.19, for a total transaction of $1,100,153.42.
• On Wednesday, July 8th, Ryan Fukushima sold 33,284 shares of Tempus AI stock. The shares were sold at an average price of $57.39, for a total value of $1,910,168.76.
• On Monday, July 6th, Ryan Fukushima sold 10,000 shares of Tempus AI stock. The shares were sold at an average price of $60.00, for a total value of $600,000.00.

Tempus AI Price Performance

Shares of NASDAQ TEM traded up $5.40 during mid-day trading on Thursday, hitting $66.65. 20,103,049 shares of the stock traded hands, compared to its average volume of 5,600,288. The company has a market cap of $12.03 billion, a PE ratio of -46.28 and a beta of 3.58. Tempus AI, Inc. has a twelve month low of $40.77 and a twelve month high of $104.32. The company has a debt-to-equity ratio of 3.06, a current ratio of 3.30 and a quick ratio of 3.16. The firm has a 50 day simple moving average of $52.44 and a two-hundred day simple moving average of $51.21.

Tempus AI (NASDAQ:TEM) last issued its earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The business had revenue of $382.49 million during the quarter, compared to analysts’ expectations of $379.69 million. During the same quarter in the prior year, the firm earned ($0.22) EPS. The business’s revenue for the quarter was up 21.6% compared to the same quarter last year. As a group, equities research analysts forecast that Tempus AI, Inc. will post -1.38 EPS for the current fiscal year.

Analyst Ratings Changes

TEM has been the subject of several recent research reports. Lake Street Capital downgraded Tempus AI to a “hold” rating in a research note on Monday, July 20th. HC Wainwright cut their target price on shares of Tempus AI from $64.00 to $56.00 and set a “buy” rating on the stock in a research report on Monday, August 3rd. TD Cowen reissued a “buy” rating on shares of Tempus AI in a report on Wednesday, July 15th. BTIG Research upped their price target on shares of Tempus AI from $70.00 to $80.00 and gave the company a “buy” rating in a research report on Thursday. Finally, Piper Sandler dropped their price target on shares of Tempus AI from $58.00 to $56.00 and set a “neutral” rating for the company in a research note on Tuesday, August 4th. Nine research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $65.69.

Key Tempus AI News

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG raised its price target to $80 from $70 and maintained a “Buy” rating, implying roughly 20% upside from the referenced price. The upgrade provided a direct catalyst for investor buying. BTIG raises Tempus AI price target
• Positive Sentiment: Investor attention is focusing on Tempus AI’s approximately $1.5 billion stock-based agreement to acquire Personalis. The deal is increasingly viewed as strategically valuable because Personalis’ genomic data and cancer-testing capabilities could strengthen Tempus’ precision-medicine and drug-development platform. Tempus AI biotech deal attracts investor attention
• Positive Sentiment: Moderna’s reported cancer-vaccine progress, alongside developments involving Merck, has encouraged investors to believe Tempus’ Personalis acquisition could benefit from increased demand for genomic data and personalized cancer treatment. The connection is indirect, but it has improved sentiment around Tempus’ strategic positioning. Tempus AI stock rises after Merck-Moderna cancer vaccine breakthrough
• Positive Sentiment: The rally was accompanied by unusually high options activity, with investors buying 40,671 call contracts—about 57% above average daily call volume—signaling increased bullish speculation and potentially reinforcing upward momentum.
• Neutral Sentiment: Technical factors also contributed: TEM moved above key moving averages, while coverage characterized the move as a possible short squeeze. These conditions can accelerate gains but may also increase volatility. Tempus AI stock technical rally

Institutional Investors Weigh In On Tempus AI

A number of institutional investors have recently made changes to their positions in the stock. JPL Wealth Management LLC acquired a new stake in shares of Tempus AI in the third quarter valued at about $26,000. Los Angeles Capital Management LLC acquired a new position in shares of Tempus AI in the fourth quarter worth approximately $27,000. Harvest Fund Management Co. Ltd acquired a new position in shares of Tempus AI in the third quarter worth approximately $38,000. Whittier Trust Co. boosted its holdings in Tempus AI by 190.0% in the first quarter. Whittier Trust Co. now owns 870 shares of the company’s stock valued at $41,000 after acquiring an additional 570 shares during the last quarter. Finally, EverSource Wealth Advisors LLC boosted its holdings in Tempus AI by 88.8% in the second quarter. EverSource Wealth Advisors LLC now owns 691 shares of the company’s stock valued at $44,000 after acquiring an additional 325 shares during the last quarter. Institutional investors own 24.22% of the company’s stock.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.